Press Releases

All Releases
View Summary Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting
Mar 26, 2015
PDF 14.5 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Reports Fourth Quarter 2014 Financial Results
Feb 26, 2015
PDF 26.6 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Biomarker-Selected Clinical Trial of MM-121 in Patients with Heregulin Positive Non-Small Cell Lung Cancer
Feb 19, 2015
PDF 20.0 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2014 Investor Conference Call
Feb 12, 2015
PDF 15.1 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Names Birgit M. Schoeberl, Ph.D. as Head of Discovery Division and Announces the Addition of Ulrik B. Nielsen, Ph.D. to Its Board of Directors
Jan 22, 2015
PDF 17.7 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Presents Additional Analyses of Phase 3 MM-398 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium
Jan 20, 2015
PDF 26.8 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Oral Presentation of Additional Analyses of MM-398 Phase 3 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium
Jan 8, 2015
PDF 17.0 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Jan 7, 2015
PDF 15.2 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces the Addition of Russell T. Ray to Its Board of Directors
Dec 17, 2014
PDF 17.3 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Presents Research on Innovative Pipeline for Patients With Breast Cancer at the 2014 San Antonio Breast Cancer Symposium
Dec 12, 2014
PDF 22.9 KB Add to Briefcase
View Summary Video Release -- Preclinical Research Differentiating the Activity of Merrimack's MM-398, Nanoliposomal Irinotecan (nal-IRI), Published in Cancer Research
Dec 4, 2014
PDF 18.3 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals to Present at Oppenheimer 25th Annual Healthcare Conference, Hold Analyst Day and Present Research on Multiple Molecules in December 2014
Dec 1, 2014
PDF 19.1 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Presents on Multiple Programs at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Nov 21, 2014
PDF 25.5 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer
Nov 19, 2014
PDF 19.2 KB Add to Briefcase
View Summary Photo Release -- Merrimack Pharmaceuticals Announces the Addition of Vivian S. Lee, Dean of University of Utah School of Medicine, to Its Board of Directors
Nov 17, 2014
PDF 75.3 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals to Present Advances on Targeted Cancer Molecules at the 2014 EORTC-NCI-AACR Symposium
Nov 13, 2014
PDF 17.5 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Reports Third Quarter 2014 Financial Results
Nov 10, 2014
PDF 25.3 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer
Nov 6, 2014
PDF 20.6 KB Add to Briefcase
View Summary FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer
Nov 5, 2014
PDF 17.8 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Timing of Third Quarter 2014 Investor Conference Call
Nov 3, 2014
PDF 15.1 KB Add to Briefcase
Showing 1-20 of 153 Page: 1 2 3 4 5 ... 8  Next 20
Add to Briefcase = add release to Briefcase

Stock Quote (NASDAQ: MACK)

Price:
11.25

Change:
+ 0.12

Day High:
11.44

Day Low:
10.57

Volume:
1,322,500

4:00 PM ET on Mar 26, 2015
Delayed ~20 min. By eSignal.

Shareholder Tools